As you all know, new and forthcoming regulations are fueling dramatic changes in pharmaceutical companies’ procedures for funding CME and planning meetings. We’ve heard from you that these changes are confusing and frustrating, especially since each company is interpreting the regulations differently. You’ve told us that it would be valuable to have a forum where you could openly discuss your challenges with your colleagues, and share strategies for surviving in the new regulatory environment